TET2-inactivating mutations result in a decrease of 5-hydroxymethylcytosine, and this parameter has been proposed as a potential diagnostic and prognostic marker for hematological cancers (Table 2, Figure 2) [56]. Here, TET2 is linked to hematopoietic and lymphoid cell neoplasm.